BARNARDS子研究:抗生素耐药、靶值达成、致病性及可及性对新生儿脓毒症结局的影响
该前瞻性子研究纳入LMIC七个国家12个中心的新生儿脓毒症病例,评估常用经验性抗生素组合的疗效。
要点
- 氨苄西林-庆大霉素治疗新生儿脓毒症死亡率显著高于头孢他啶-阿米卡星。
- 多数LMIC站点表示抗生素费用会影响新生儿脓毒症治疗决策。
核心结论
- LMIC新生儿脓毒症经验性使用氨苄西林-庆大霉素因高耐药、高耐药频率和低靶值达成概率而受到质疑。
- 推荐抗生素治疗时需考虑可及性和可负担性。
研究设计与样本
- BARNARDS前瞻性观察队列子研究,纳入7国12个中心0-60日龄疑似脓毒症新生儿,排除死产儿。
- 对培养确诊脓毒症的细菌分离株行全基因组测序和最低抑菌浓度测定,收集至60日龄结局数据。
- 分析抗生素使用与结局,生存分析校正出生及病原相关临床混杂变量。
- 评估耐药谱、药代动力学-药效学靶值达成概率及耐药频率,问卷调查卫生结构和抗生素费用。
主要发现
- 442例新生儿476次处方有WGS数据(除印度外所有国家),共分离457株病原体。
关键数值与推荐
- 7国中6国(除南非)站点表示抗生素费用会影响新生儿脓毒症治疗。
临床怎么用
- LMIC新生儿脓毒症经验性治疗应重新评估氨苄西林-庆大霉素方案。
- 选择抗生素需结合当地耐药谱、靶值达成概率及可负担性。
局限性
- 抗生素效应与国家效应无法区分。
- WGS子集未包括印度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sepsis is a major contributor to neonatal mortality, particularly in low-income and middle-income countries (LMICs). WHO advocates ampicillin-gentamicin as first-line therapy for the management of neonatal sepsis. In the BARNARDS observational cohort study of neonatal sepsis and antimicrobial resistance in LMICs, common sepsis pathogens were characterised via whole genome sequencing (WGS) and antimicrobial resistance profiles. In this substudy of BARNARDS, we aimed to assess the use and efficacy of empirical antibiotic therapies commonly used in LMICs for neonatal sepsis. METHODS: In BARNARDS, consenting mother-neonates aged 0-60 days dyads were enrolled on delivery or neonatal presentation with suspected sepsis at 12 BARNARDS clinical sites in Bangladesh, Ethiopia, India, Pakistan, Nigeria, Rwanda, and South Africa. Stillborn babies were excluded from the study. Blood samples were collected from neonates presenting with clinical signs of sepsis, and WGS and minimum inhibitory concentrations for antibiotic treatment were determined for bacterial isolates from culture-confirmed sepsis. Neonatal outcome data were collected following enrolment until 60 days of life. Antibiotic usage and neonatal outcome data were assessed. Survival analyses were adjusted to take into account potential clinical confounding variables related to the birth and pathogen. Additionally, resistance profiles, pharmacokinetic-pharmacodynamic probability of target attainment, and frequency of resistance (ie, resistance defined by in-vitro growth of isolates when challenged by antibiotics) were assessed. Questionnaires on health structures and antibiotic costs evaluated accessibility and affordability. FINDINGS: Between Nov 12, 2015, and Feb 1, 2018, 36 285 neonates were enrolled into the main BARNARDS study, of whom 9874 had clinically diagnosed sepsis and 5749 had available antibiotic data. The four most commonly prescribed antibiotic combinations given to 4451 neonates (77·42%) of 5749 were ampicillin-gentamicin, ceftazidime-amikacin, piperacillin-tazobactam-amikacin, and amoxicillin clavulanate-amikacin. This dataset assessed 476 prescriptions for 442 neonates treated with one of these antibiotic combinations with WGS data (all BARNARDS countries were represented in this subset except India). Multiple pathogens were isolated, totalling 457 isolates. Reported mortality was lower for neonates treated with ceftazidime-amikacin than for neonates treated with ampicillin-gentamicin (hazard ratio [adjusted for clinical variables considered potential confounders to outcomes] 0·32, 95% CI 0·14-0·72; p=0·0060). Of 390 Gram-negative isolates, 379 (97·2%) were resistant to ampicillin and 274 (70·3%) were resistant to gentamicin. Susceptibility of Gram-negative isolates to at least one antibiotic in a treatment combination was noted in 111 (28·5%) to ampicillin-gentamicin; 286 (73·3%) to amoxicillin clavulanate-amikacin; 301 (77·2%) to ceftazidime-amikacin; and 312 (80·0%) to piperacillin-tazobactam-amikacin. A probability of target attainment of 80% or more was noted in 26 neonates (33·7% [SD 0·59]) of 78 with ampicillin-gentamicin; 15 (68·0% [3·84]) of 27 with amoxicillin clavulanate-amikacin; 93 (92·7% [0·24]) of 109 with ceftazidime-amikacin; and 70 (85·3% [0·47]) of 76 with piperacillin-tazobactam-amikacin. However, antibiotic and country effects could not be distinguished. Frequency of resistance was recorded most frequently with fosfomycin (in 78 isolates [68·4%] of 114), followed by colistin (55 isolates [57·3%] of 96), and gentamicin (62 isolates [53·0%] of 117). Sites in six of the seven countries (excluding South Africa) stated that the cost of antibiotics would influence treatment of neonatal sepsis. INTERPRETATION: Our data raise questions about the empirical use of combined ampicillin-gentamicin for neonatal sepsis in LMICs because of its high resistance and high rates of frequency of resistance and low probability of target attainment. Accessibility and affordability need to be considered when advocating antibiotic treatments with variance in economic health structures across LMICs. FUNDING: The Bill & Melinda Gates Foundation.
引用
- Thomson KM, Dyer C, Liu F, et al. Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). Lancet Infect Dis. 2021. PMID: 34384533. doi:10.1016/S1473-3099(21)00050-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。